Weight-loss drug competition heats up with growing pill market
Published On Sep 17, 2024, 5:32 PM
The competition in the weight-loss drug market is increasing as several companies try to challenge the dominance of Novo Nordisk and Eli Lilly. New oral GLP-1 medications are being developed, potentially offering an alternative to injections. Roche has reported early-stage trial results indicating a 6.1% weight loss with its oral option, while Eli Lilly's candidate has shown a more impressive 14.7% weight loss. Concerns about side effects have emerged, particularly for Roche's pill, impacting its stock performance. Market analysts are skeptical about new entrants unless they significantly differentiate from established products.